Phase 3 Readout~month

Phase 3 Topline: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide Plus Androgen Deprivati

Indication
Biochemically Recurrent Prostate Cancer

Other upcoming events for RPRX

Phase 3 ReadoutPhase 3 Topline: A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide With Continued Versus Intermitte
Patent ExpiryPatent/Exclusivity Expiry: COMETRIQ
Patent ExpiryPatent/Exclusivity Expiry: CABOMETYX

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide Plus Androgen Deprivati — RPRX Phase 3 Readout | BioSniper